# Early Bactericidal Activity of TBA-7371 in Pulmonary Tuberculosis

> **NCT04176250** · PHASE2 · COMPLETED · sponsor: **Gates Medical Research Institute** · enrollment: 93 (actual)

## Conditions studied

- Pulmonary Tuberculosis

## Interventions

- **DRUG:** TBA-7371
- **DRUG:** TBA-7371
- **DRUG:** TBA-7371
- **DRUG:** TBA-7371
- **DRUG:** TBA-7371
- **DRUG:** HRZE

## Key facts

- **NCT ID:** NCT04176250
- **Lead sponsor:** Gates Medical Research Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-01-16
- **Primary completion:** 2022-10-05
- **Final completion:** 2022-10-05
- **Target enrollment:** 93 (ACTUAL)
- **Last updated:** 2024-04-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04176250

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04176250, "Early Bactericidal Activity of TBA-7371 in Pulmonary Tuberculosis". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04176250. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*